Business Context and Reporting Period
Adagio Therapeutics, Inc. (now Invivyd, Inc.) filed a Current Report on Form 8-K dated February 14, 2022. The filing concerns a proposed chief executive officer transition, not a periodic financial report.
Management Change
- Tillman Gerngross, Ph.D. agreed in principle to resign as Chief Executive Officer.
- The Board intended to appoint David Hering, M.B.A., then the Company’s Chief Operating Officer, as Interim Chief Executive Officer.
- Dr. Gerngross agreed to transfer the CEO duties to Mr. Hering.
- The Company stated that additional details would be provided in a subsequent press release and Form 8-K.
Financial Metrics and Other Key Items
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, operating guidance, or other financial metrics.
Outlook, Risks, and Unusual Items
The principal disclosed event is a senior-management transition. The filing does not explain the reasons for Dr. Gerngross’s planned resignation, specify the duration of the interim appointment, or describe any related compensation, severance, or succession arrangements.
Important Facts to Verify
- Whether the Board formally appointed David Hering as Interim CEO and the effective date of the appointment.
- Whether Dr. Gerngross completed his resignation and whether he retained any other role with the Company.
- Details of the transition, including compensation, severance, governance changes, and the search for a permanent CEO, in subsequent filings.
- Any business or financial impact associated with the management change.